TGFB1 and metastatic malignant neoplasm: XPA-42-089, a pan-specific anti-TGF-β mAb was tested in a study by Dodagatta-Marristudy et al. [428] to address the challenges of low response rates in checkpoint blockade immunotherapy for metastatic cancer patients, aiming to identify mechanisms to overcome resistance.